Epithelial ovarian cancer
Conditions
Interventions
Case group:None
Sponsors
The First Affiliated Hospital of University of Science and Technology of China
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1.Patients with EOC who were first diagnosed in each center were >18 years old; 2.All patients received standard staging, primary tumor cell reduction or intermediate tumor cell reduction, and EOC was confirmed by 2 or more chief pathologists before enrollment. 3.The time of diagnosis of enrolled patients should be followed up for at least 12 months for the last enrolled patient between January 1, 2018 and December 31, 2023; 4.Complete clinical data of patients: age at diagnosis of cancer, BMI, menopausal status, complications and family history; Tumor markers (CA125/CA199/HE4), blood routine, albumin and prealbumin, CRP, D-dimer and imaging data before treatment; Intraoperative abdominal water volume, SCS and DDS scores, postoperative pathological primary lesion size and location, lymph node size, location and metastasis, ER, PR, PAX8, Ki67, etc. 5.Patients may have a history of breast cancer and have been cured for nearly 2 years at the time of enrollment without treatment or recurrence; 6.For neoadjuvant chemotherapy patients, if CA125/CEA<25, gastrointestinal origin should be excluded by gastroenteroscopy; 7.At the time of study enrollment, patients who voluntarily signed informed consent forms approved by the Research Ethics Committee (EC) were informed of the potential risks, benefits, and discomforts of participating in the study after being appropriately informed of the nature of the study.
Exclusion criteria
Exclusion criteria: 1.There is no clear pathological diagnosis basis; 2.Patients who have participated in other biomedical studies or received experimental therapy within the past 30 days, unless approved by the investigator; 3.There are known contraindications to the upcoming first-line chemotherapy or second-line or multi-line chemotherapy; 4.Have a history of malignant tumors or co-existing other malignant tumors or multiple primary tumors (excluding breast cancer); 5.With HIV, hepatitis B, hepatitis C and other active infectious diseases or active rheumatic system diseases; 6.Ineligible for inclusion, such as severe or uncontrolled bacterial, fungal, or viral infection or other conditions that may interfere with patients' participation in the study or evaluation of the study results; 7.The main information is not complete or the patients are lost to follow-up without reason during the study; 8.Unwillingness to sign informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival; | — |
Countries
China
Contacts
Public ContactZhou Ying
The First Affiliated Hospital of University of Science and Technology of China
Outcome results
None listed